{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:16:30Z","timestamp":1760148990451,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>This comprehensive collection of papers contains a wide range of studies and observations centered on antiviral therapies, with a particular focus on HIV and other viral infections such as monkeypox and SARS-CoV-2 [...]<\/jats:p>","DOI":"10.3390\/v15071411","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T01:49:32Z","timestamp":1687398572000},"page":"1411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Issue \u201cEfficacy and Safety of Antiviral Therapy\u201d"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8959-1403","authenticated-orcid":false,"given":"Agnese","family":"Colpani","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-5400","authenticated-orcid":false,"given":"Andrea","family":"De Vito","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-2273","authenticated-orcid":false,"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gunder, L.C., Johnson, H.R., Yao, E., Moyer, T.H., Green, H.A., Sherer, N., Zhang, W., and Carchman, E.H. (2023). Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease. Viruses, 15.","DOI":"10.3390\/v15041013"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"De Vito, A., Colpani, A., Saderi, L., Puci, M., Zauli, B., Fiore, V., Fois, M., Meloni, M.C., Bitti, A., and Di Castri, C. (2022). Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression. Viruses, 15.","DOI":"10.3390\/v15010071"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Del Borgo, C., Garattini, S., Bortignon, C., Carraro, A., Di Trento, D., Gasperin, A., Grimaldi, A., De Maria, S.G., Corazza, S., and Tieghi, T. (2023). Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir\/r: A Real-World Comparison in the First Ten Months of Use. Viruses, 15.","DOI":"10.3390\/v15041025"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1002\/jmv.28011","article-title":"Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: A real-life experience","volume":"94","author":"Colpani","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Mengato, D., Sasset, L., Ferrari, A., Gardin, S., Scaglione, V., Bonadiman, N., Calandrino, L., Cavinato, S., and Trivellato, S. (2023). Molnupiravir and Nirmatrelvir\/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study. Viruses, 15.","DOI":"10.3390\/v15020384"},{"key":"ref_6","first-page":"2435","article-title":"Early combination treatment with existing HIV antivirals: An effective treatment for COVID-19?","volume":"25","author":"Dallocchio","year":"2021","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100993","DOI":"10.1016\/j.eclinm.2021.100993","article-title":"Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial","volume":"38","author":"Parienti","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/hiv.13228","article-title":"The use of tenofovir in patients with COVID-19","volume":"23","author":"Kow","year":"2022","journal-title":"HIV Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Marocco, R., Del Borgo, C., Tortellini, E., Garattini, S., Carraro, A., Di Trento, D., Gasperin, A., Grimaldi, A., Tieghi, T., and Belvisi, V. (2023). Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. Viruses, 15.","DOI":"10.3390\/v15040947"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mussini, C., Cozzi-Lepri, A., Meschiari, M., Franceschini, E., Burastero, G., Faltoni, M., Franceschi, G., Iadisernia, V., Volpi, S., and Dessilani, A. (2023). Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study. Viruses, 15.","DOI":"10.3390\/v15020294"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Candela, C., Raccagni, A.R., Bruzzesi, E., Bertoni, C., Rizzo, A., Gagliardi, G., Canetti, D., Gianotti, N., Mileto, D., and Gismondo, M.R. (2023). Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics. Viruses, 15.","DOI":"10.3390\/v15030667"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Vinuesa, D., Garc\u00eda-Vallecillos, C., Mu\u00f1oz-Medina, L., Sequera, S., Javier, R., L\u00f3pez-Ruz, M.\u00c1., Sadyrbaeva-Dolgova, S., and Pasquau, J. (2022). Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV. Viruses, 14.","DOI":"10.3390\/v14122626"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Kim, J., Lee, J.A., Kim, C.H., Ahn, J.Y., Jeong, S.J., Ku, N.S., Choi, J.Y., Yeom, J.S., and Song, Y.G. (2022). Real-World Effectiveness, Tolerability, and Safety of Dolutegravir\/Lamivudine in Korea. Viruses, 14.","DOI":"10.3390\/v14112558"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/apc.2021.0089","article-title":"Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study","volume":"35","author":"Taramasso","year":"2021","journal-title":"AIDS Patient Care STDs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five Years with Dolutegravir Plus Lamivudine as a Switch Strategy: Much More than a Positive Finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fabbiani, M., Masini, M., Rossetti, B., Ciccullo, A., Borghi, V., Lagi, F., Capetti, A., Colafigli, M., Panza, F., and Baldin, G. (2023). Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Na\u00efve AIDS- or Late-Presenting HIV-Infected Patients. Viruses, 15.","DOI":"10.3390\/v15051123"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lazzaro, A., Bianchini, D., Gentilini Cacciola, E., Mezzaroma, I., Falciano, M., Andreoni, C., Fimiani, C., Santinelli, L., Maddaloni, L., and Bugani, G. (2023). Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. Viruses, 15.","DOI":"10.3390\/v15061222"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Iannone, V., Passerotto, R.A., Lamanna, F., Steiner, R.J., Lombardi, F., Salvo, P.F., Dusina, A., Farinacci, D., Borghetti, A., and Di Giambenedetto, S. (2023). Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen. Viruses, 15.","DOI":"10.3390\/v15051046"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"De Vito, A., Ricci, E., Menzaghi, B., Orofino, G., Vito Martinelli, C., Squillace, N., Taramasso, L., Vittorio De Socio, G., Molteni, C., and Valsecchi, L. (2023). Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study. Viruses, 15.","DOI":"10.3390\/v15030720"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:58:17Z","timestamp":1760126297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071411"],"URL":"https:\/\/doi.org\/10.3390\/v15071411","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,6,21]]}}}